Fig. 5From: Midazolam increases cisplatin-sensitivity in non-small cell lung cancer (NSCLC) via the miR-194-5p/HOOK3 axisUpregulation of HOOK3 rescued cell viability in midazolam and cisplatin co-treated CR-NSCLC cells. We performed A, B MTT assay and C, D trypan blue staining assay to respectively examine cell proliferation and viability in the CR-NSCLC cells. E–G Cell apoptosis ratio in CR-NSCLC cells was examined by FCM assay. Individual experiment contained at least 3 repetitions, and *P < 0.05, **P < 0.01, and ***P < 0.001 was considered as statistical significanceBack to article page